Physician profile
Randi Slone
NPI 1760947030
$3,685.89
in general payments reported to CMS, 2019-2025
29 companies · $736 in 2025
The $736 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $246 · 2023: $1,302 · 2024: $1,290 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,327.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $929.46 | 2022-2025 | |
| Axsome Therapeutics, INC. | $514.57 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $349.33 | 2023-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $292.54 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $162.12 | 2021-2024 | Breztri, Airsupra |
| Lundbeck LLC | $139.87 | 2023-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $128.77 | 2023-2025 | Caplyta |
| Pfizer INC. | $115.57 | 2021-2025 | |
| Amgen INC. | $112.15 | 2021-2024 | Repatha, Otezla |
| Novo Nordisk INC | $93.23 | 2021-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $80.32 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Dexcom, INC. | $78.20 | 2022-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $73.61 | 2021-2025 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $71.33 | 2024 | |
| Neurocrine Biosciences, INC. | $68.86 | 2023-2025 | Ingrezza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.30 | 2024-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $59.06 | 2023 | |
| Alkermes, INC. | $55.18 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Astellas Pharma US INC | $50.06 | 2023-2024 | Veozah |
| Vanda Pharmaceuticals INC. | $49.40 | 2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $41.26 | 2023-2024 | Invega Trinza, Invega Sustenna, Spravato |
| Hologic Sales and Service, LLC | $31.65 | 2022-2023 | Aptima, Thinprep 2000 Processor |
| Indivior INC. | $25.75 | 2023 | Perseris |
| Xeris Pharmaceuticals, INC. | $25.29 | 2021-2024 | Gvoke Hypopen |
| Radius Health, INC. | $19.23 | 2025 | Tymlos |
| Acadia Pharmaceuticals INC | $14.40 | 2023 | Nuplazid |
| Exact Sciences Corporation | $13.23 | 2023 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $12.80 | 2022 | |
| Daiichi Sankyo INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randi Slone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.